|
市場調査レポート
バイオマーカーの最新動向
Advances in Biomarkers
|
Abstract
This research service outlines the key global developments in the field of
biomarkers.
Table of Contents
1. EXECUTIVE SUMMARY
Macroscopic View of Biomarkers
- Go Biological with a Biomarker
- Types of Biomarkers
- Omics to Know-Omics Now
Scope and Methodology
- Scope and Segmentation of the Research Service
- Research Methodology
2. BIOMARKERS IN DRUG DISCOVERY
The Biomarker Method in Drug Discovery and Development
- Biomarkers May Relieve the Drug Discovery Bottleneck
- See Path to a Biomarker
Noteworthy Innovations
- Biomarker Serves as a Green Signal for a Small Molecule Drug and a Red
Alert for Another
- Stack of Biomarkers Aid in Understanding Drug Toxicity
- Proteins Find it Difficult to Remain Undetected
- A Clear Vision and View for Metabolomics
Case Studies of Targeted Diagnostics for Targeted Therapeutics
- Diagnostic as a Companion to Therapeutic
- Wealth of Research on Anti-EGFR Therapy
- HIV Takes Diversion and Tricks the Drug
- Companion Diagnostics Make a Footprint
3. BIOMARKERS IN CLINICAL DIAGNOSTICS
The Biomarker Role in Clinical Diagnostics
- Better Diagnostics is Equal to Better Treatment
- Noteworthy Innovations in Oncology
- Noteworthy Innovation in Nononcology Areas
4. STRATEGIC EVALUATION OF THE BIOMARKER INDUSTRY
Application Trend Analysis
- Biomarkers Research Direction
- Biomarkers Promise to Deliver Sooner in Oncology
AHP--Prioritization of Biomarker Technologies
- Definition of Criteria
- AHP Process and Computation for Goal Node and Level 0 Criteria
- AHP Process and Computation for Goal Node and Level 1 Criteria
- Final Priorities and Analyst Insights
Force Field Analysis
- Growth Drivers and Growth Inhibitors
- Strategies for Change
5. STRATEGIC EVALUATION OF PATENTS AND KEY CONTACTS
Strategic Evaluation of Patents
- World Biomarker IP Portfolio--Drug Discovery
- Key Patents in Oncology--Diagnostics--Pertaining to Developments in
Chapter 3.1
- Key Patents in Nononcology Areas--Diagnostics--Pertaining to Developments
in Chapter 3.1
Key Contacts and Appendix
6. DECISION SUPPORT DATABASE
Database Tables
- Government Investment in Biotechnology--World (2002 to 2012)
- Percent Government R&D Investment in Biotechnology--World (2002 to 2012)
- Global Pharmaceutical R&D Expenditure (2002 to 2012)
- Global Percentage Pharmaceutical R&D Expenditure (2002 to 2012)
|
